Business Owner
OB
OneThree Biotech
onethree.bio
Website unreachable since Oct 18, 2026
OneThree Biotech utilizes biology-driven artificial intelligence to enhance the drug discovery process by predicting molecular interactions and optimizing lead compounds. This approach reduces the time and cost associated with traditional drug development methods, enabling more efficient identification of viable therapeutic candidates.
- Artificial Intelligence
- Biotechnology
Updated 23 months ago
Funding
Raised to date
$2.8MRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Product
Problem
Traditional drug discovery methods are time-consuming and costly, often involving extensive trial-and-error processes to identify viable therapeutic candidates. Predicting molecular interactions and optimizing lead compounds remains a significant challenge, hindering the efficient development of new drugs.
Solution
OneThree Biotech aims to accelerate drug discovery by leveraging biology-driven artificial intelligence to predict molecular interactions and optimize lead compounds. Their approach seeks to reduce the time and cost associated with traditional drug development by enabling more efficient identification of promising therapeutic candidates. By using AI to analyze biological data, OneThree Biotech hopes to improve the accuracy and speed of identifying molecules with the potential to become effective drugs. This technology could help pharmaceutical companies and research institutions bring new treatments to market faster and more affordably.
Target Audience
OneThree Biotech's primary customers are pharmaceutical companies and research institutions involved in drug discovery and development.
Features
- AI-driven prediction of molecular interactions
- Optimization of lead compounds using biological data analysis